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GUIDELINE 
Guideline for the use of beta-interferons in patients with 
multiple sclerosis - a South African proposal 
Multiple Sclerosis Advisory Committee of the Neurological Association of South Africa (NASA) 
Aim. To determine guidelines for use of beta-interferons in 
South African patients with multiple sclerosis. 
Method. Review of existing international protocols. Opinions 
of South African neurologists who have an interest in 
Multiple sclerosis (MS) is an inflammatory immune-mediated 
demyelinating disease that affects the central nervous system 
(brain, optic nerves and spinal cord). It is the leading cause of 
chronic neurological disability in young adults worldwide. It 
has a high prevalence in Caucasian people, in particular across 
the northern parts of Europe, Northern Scotland, Scandinavia 
and North America. It is much less common in the tropical 
areas of the world. 
The mean age of onset of the disease is in the early thirties, 
with a female preponderance. The aetiology remains unknown 
but there is strong evidence that the disease is caused by a 
combination of environmental, genetic and as yet 
undetermined factors. 
The disease has a variable course and is categorised into 
different forms based on natural history. Remitting and 
relapsing MS (RRMS) is the commonest form of the disease. 
Primary progressive (PPMS) and secondary progressive 
(SPMS) are the two other recognised types of MS. A further 
category defined as clinically isolated syndromes (CIS) has 
been described in which patients suffer a single attack (e.g. 
optic neuritis) with objective clinical evidence of a lesion (on 
magnetic resonance imaging (MRI) scan of the brain). If 
dissemination can be shown in time and space on MRI then in 
the appropriate context MS may be diagnosed in these patients. 
Alternatively a second attack will also suffice to establish MS 
diagnosis. Benign MS refers to a group (10%) of patients 
(typically with RRMS) who do well for many years and hence 
are defined as 'benign'. Typically these patients have many 
attacks but little cumulative deficit. Some also have few attacks 
separated by long intervals. 
In the past, the diagnosis of MS was essentially clinical. 
However, the advent of MRI has made a major impact in terms 
of diagnosis. With MRI becoming more widely available, early 
diagnosis of MS has become a reality. MRI has become the 
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multiple sclerosis. 
Conclusions. The main indication for interferon use is the 
relapsing and remitting form of multiple sclerosis. 
S Afr Med J 2004; 94: 917-921. 
principal diagnostic tool in investigation of patients with 
suspected MS. Other modalities that may assist in diagnosis 
include cerebrospinal fluid (CSF) oligoclonal antibodies and 
evoked potential tests. Criteria for the diagnosis of MS based 
on clinical, MRI and these ancillary tests have now been 
established. The first of these criteria for diagnosis were based 
on Poser's 1983 criteria1 (Appendix A). More recently in 2001 
newer criteria based more strongly on MRI findings have been 
proposed by McDonald et al. (Appendix B).' These revised 
criteria allow for early diagnosis and diagnosis of 
monosymptomatic disease. 
The treatment of MS has been refined and redefined over the 
past few decades. The hallmarks of treatment are immuno-
suppression and immunomodulation. Immunosuppression 
uses high doses of intravenous steroids (methylprednisolone). 
This is used to treat acute relapses. The treatment is nonspecific 
and targets the generalised expected disturbance in immune 
mechanisms during an acute attack. Given the high doses, the 
side-effect profile of this kind of treatment can be considerable 
and therefore its use is restricted to a pulse for a maximum of 5 
days. There is no evidence for the use of prolonged treatment 
with intravenous or oral steroids. 
Immunomodulatory therapy is more specifically directed at 
altering the natural history and course of the disease. 
Essentially two groups of agents have been established to have 
beneficial effect in this regard. The first and most widely used 
of these are the interferons (IFNs). The other agent that has 
similar beneficial effect is the drug glatiramer acetate. As this 
drug is not currently available in South Africa, we will not 
discuss it any further. 
The IFNs are available in South Africa in two forms, IFN- lilfJ 
beta-1a (Avonex and Rebif) and IFN-beta-lb (Betaferon). These 
are different forms of recombinant IFN-beta. The IFNs are 
cytokines that form a natural part of the human immune 
system. Two major types are identified: type 1 - IFN alpha/ 
interferon beta, and type 2- interferon gamma. The IFNs are 
secreted after activation by invading organisms. The type 1 
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IFNs have anti-inflammatory effects through IFN-stimulated 
gene products. The anti-inflammatory effect of these IFNs 
forms the basis of their immunomodulatory effects in MS. The 
IFNs have been shown to:'·' (i) increase the time of 
development of a second relapse in early MS; (ii) reduce the 
frequency and severity of relapses in RRMS; (iii) slow the 
accumulation of physical disability (4-year follow-up study); 
and (iv) reduce the MRI burden of the disease. 
There is strong evidence that these agents are beneficial in 
patients with RRMS. There is no recognised benefit in patients 
with PPMS, but there is evidence of benefit from IFN therapy 
in SPMS with frequent relapses. There is now accumulating 
evidence (not yet as conclusive as evidence for RRMS) for 
benefit in patients with CIS.'' A relevant issue, especially in our 
country and perhaps even worldwide, is the cost of 
immunomodulatory agents. In South Africa, regardless of the 
type used, the average cost per annum for an IFN is in the 
region of R85 000. In RRMS the benefits of the IFNs have been 
shown to outweigh costs.'·' This has prompted the National 
Health Service (NHS) in the UK to allow IFN use in patients 
with RRMS and SPMS with frequent relapses. 
To address these issues a consensus open meeting was held 
of South African neurologists (academic and private) interested 
in MS. The group evaluated the current literature regarding 
IFN treatment in MS and also assessed the criteria of the British 
Neurological Association. To assist South African neurologists 
and health care providers and funders in determining the use 
of IFNs in our patients with MS, the following criteria were 
recommended. 
1. Remitting and relapsing MS 
For this form of MS the Committee agreed that the diagnosis 
should be based on the occurrence of at least 2 attacks of the 
disease in the previous 2 years. An attack is defined as a focal 
neurological event and the diagnosis should meet the 
McDonald criteria. The Committee also agreed that there was 
no contraindication to the use of IFNs in this group. 
Patients above 18 years of age were to be included in this 
category. No upper age limit was considered necessary. In this 
group any patient who can stand and step/walk 
independently with an Expanded Disability Status Scale 
(EDSS) (Appendix C) score of less than 5.5 in the 
stable/remission phase should be included. 
IJBI 2. Secondary progressive MS 
Two groups of SPMS are recognised: 
Secondary progressive with no relapses. In this group the 
Committee felt that IFN was not indicated unless, on regular 
follow-up, relapses were identified. Again, a relapse is defined 
in terms of McDonald's criteria. 
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Secondary progressive with relapses. In this group the 
Committee felt that INF was indicated but that the following 
should be adhered to: 
• relapses should be the dominant cause of disability 
• EDSS score of less than or equal to 6.5 
• at least 2 disabling relapses (a change in EDSS score of at 
least 1) in the previous 2 years 
• age group - no age restriction 
• no contraindications. 
3. Clinically isolated syndromes 
In this group of patients, 2 separate categories were identified. 
3.1 Without any other evidence of disease, i.e. negative MRI 
and not in keeping with McDonald's criteria. For these patients 
IFN therapy is not indicated. 
3.2 Those with evidence of burden of disease on MRI (white 
matter lesions) - no IFN treatment is recognised at this stage. 
However the Committee reserves the right to modify this 
should further evidence from randomised, controlled trials 
become available. 
In general, in this category of patients the Committee felt 
that there was insufficient evidence to support use of IFN 
therapy regardless of paraclinical or any other evidence. 
4. Primary progressive MS 
IFN use is not indicated in this category of patients at this time. 
Certain other comments and recommendations were made 
by the Committee. 
4.1. The diagnosis of MS has to be established by a neurologist. 
The neurologist has to apply the criteria as proposed by 
McDonald et al., 2001. 
4.2. The use of IFN therapy has to be initiated by a neurologist. 
A general practitioner or other specialist may assist the 
neurologist in terms of follow-up. It therefore follows that the 
neurologist will be involved in the motivation for the use of 
interferon in a selected patient. 
4.3. Cost mitigates against the widespread use of IFN as a 
prophylactic treatment for MS. 
4.4. The use of IFN implies that the patient has active or 
ongoing disease. 
4.5. The problem of cost has to be taken out of the equation in 
patients fulfilling criteria for use of IFN. 
4.6. The Committee felt that there is no evidence to support the 
use of one IFN type over the other. Switching from one IFN 
type to another would not result in an added benefit. There 
were insufficient head-to-head data in this regard. 
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5. Stopping of treatment 
The Committee felt that this was an important issue and the 
following criteria were recommended for stopping IFN therapy 
in a particular patient: 
• intolerable adverse effects (medical contraindications) 
• planned/unplanned pregnancy 
• lack of efficacy. 
These guidelines are based on current literature evidence, and the 
opinion of the Committee at this time is subject to change with 
new emerging data. 
The Committee consisted of the following members: Prof 
Girish Modi, Head of Neurology, University of the Witwaters-
rand (Chairperson); Prof Roland Eastman, Head of Neurology, 
University of Cape Town; Prof Pierre Bill, Department of 
Neurology, University of KwaZulu-Natal; Prof Abie Kruger, 
Head of Neurology, University of the Free State; Prof David 
Saffer, University of the Witwatersrand; Dr Simon Kessler, private 
practice, Cape Town; Dr Louis Biermann, private practice, 
Pretoria; Dr Bhupendra Bhagwan, private practice, Durban; Dr 
Appendix A. The Poser criteria 
• Clinically definite MS 
• 2 attacks and clinical evidence of 2 separate lesions 
• 2 attacks, clinical evidence of 1 and paraclinical evidence 
of another separate lesion 
• Laboratory-supported definite MS 
• 2 attacks, either clinical or paraclinical evidence of 1 
lesion, and cerebrospinal fluid (CSF) immunological 
abnormalities 
• 1 attack, clinical evidence of 2 separate lesions and CSF 
abnormalities 
• 1 attack, clinical evidence of 1 and paraclinical evidence 
of another separate lesion, and CSF abnormalities 
• Clinically probable MS 
• 2 attacks and clinical evidence of 1 lesion 
• 1 attack and clinical evidence of 2 separate lesions 
• 1 attack, clinical evidence of 1 lesion, and paraclinical 
evidence of another separate lesion 
• Laboratory-supported probable MS 
• 2 attacks and CSF abnormalities 
What is an attack? 
• Neurological disturbance of kind seen in MS 
• Subjective report or objective observation 
• 24 hours' duration, minimum 
• Excludes pseudoattacks, single paroxysmal episodes 
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Dominique Giampaolo, private practice, Johannesburg. 
All members of the Committee had to disclose any 
involvement, financial or otherwise, with the IFN pharma-
ceutical industry. Professor Eastman indicated that he had on 
occasion advised Serono (manufacturers of the IFN Rebif). He 
is also on the Medscheme Advisory Board regarding multiple 
sclerosis. Professor Kruger has attended an advisory meeting 
for Serono. Dr Biermann had received travel and meeting 
support previously and had a meeting sponsored by the IFN 
pharmaceutical industry, with the medical aid industry to try 
to resolve IFN-related issues. Dr Giampaolo has served on a 
Serono Advisory Board and also received travel and meeting 
support from Pharmaplan. Professor Saffer has received travel 
support for an advisory meeting. No other members received 
any support to date. 
The meeting was sponsored by Pharmaplan, Serono, and 
Schering. No representative of these companies was present 
during the meeting or participated in the discussions at the 
meeting. It was agreed that the Committee would formulate its 
recommendations independently and would specifically not 
target any of the IFNs. 
Determining time between attacks 
• 30 days between onset of event 1 and onset of event 2 
How is 'abnormality' in paraclinical tests determined? 
• Magnetic resonance imaging (MRI) 3 out of 4: 
• 1 gadolinium (Gd)-enhancing or 9 T2 hyperintense 
lesions if no Gd-enhancing lesion 
• 1 or more infra tentorial lesions 
• 1 or more juxtacortical lesions 
• 3 or more periventricular lesions 
(1 spinal cord lesion = 1 brain lesion) 
• Cerebrospinal fluid (CSF) 
• Oligoclonal immunoglobin (IgG) bands in CSF (and not 
serum), OR 
• Elevated IgG index 
• Evoked potentials (EP) 
• Delayed but well-preserved wave form 
What provides MRI evidence of dissemination in time? 
• A Gd-enhancing lesion demonstrated in a scan done at least 
3 months following onset of clinical attack at a site different IJ:D 
from attack, OR 
• In absence of Gd-enhancing lesions at 3-month scan, follow-
up scan after an additional 3 months showing Gd-lesion or 
new T2 lesion 
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Appendix B. McDonald criteria 
Clinical presentation 
• 2 or more attacks (relapses) 
• 2 or more objective clinical lesions 
• 2 or more attacks 
• 1 objective clinical lesion 
• 1 attack 
• 2 or more objective clinical lesions 
• 1 attack 
• 1 objective clinical lesion 
(monosymptomatic presentation) 
Insidious neurological progression 
suggestive of MS 
(primary progressive MS) 
Appendix C. Expanded Disability 
Status Scale (EDSS) 
The Kurtzke Expanded Disability Status Scale (EDSS) is a 
method of quantifying disability in MS (for scores see box on p. 
921). The EDSS replaced the previous Disability Status Scales 
which used to bunch people with MS in the lower brackets. 
The EDSS quantifies disability in 8 functional systems (FS) 
and allows neurologists to assign a functional system score 
(FSS) in each of these. The functional systems are: 
• pyramidal 
• cerebellar 
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Additional data needed 
None; clinical evidence will suffice 
(additional evidence desirable but must be consistent 
with MS) 
Dissemination in space demonstrated by: 
• MRI 
• or a positive CSF and 2 or more MRllesions consistent 
withMS 
• or further clinical attack involving different site 
Dissemination in time, demonstrated by: 
• MRI 
• or second clinical attack 
Dissemination in space demonstrated by: 
• MRI 
• or positive CSF and 2 or more MRI lesions consistent 
withMS 
and 
Dissemination in time demonstrated by: 
• MRI 
• or second clinical attack 
Positive CSF 
and 
Dissemination in space demonstrated by: 
• MRI evidence of 9 or more T2 brain lesions 
• or 2 or more spinal cord lesions 
• or 4 - 8 brain and 1 spinal cord lesion 
or positive visual evoked potentials (VEP) with 4 - 8 MRI 
lesions 
• or positive VEP with < 4 brain lesions plus 1 spinal 
cord lesion 
and 
Dissemination in time demonstrated by: 
• MRI 
• or continued progression for 1 year 
• brainstem 
• sensory 




EDSS steps 1.0- 4.5 refer to people with MS who are fully 
ambulatory. EDSS steps 5.0- 9.5 are defined by the 
























Normal neurological examination 
No disability, minimal signs in 1 FS 
No disability, minimal signs in more than 1 FS 
Minimal disability in 1 FS 
Mild disability in 1 FS or minimal disability in 2 FSs 
Moderate disability in one FS, or mild disability in 3 or 4 FSs. Fully ambulatory 
Fully ambulatory but with moderate disability in 1 FS and more than minimal disability in several others 
Fully ambulatory without aid, self-sufficient, up and about some 12 hours a day despite relatively severe disability; 
able to walk some 500 m without aid or rest 
Fully ambulatory without aid, up and about much of the day, able to work a full day, may otherwise have some 
limitation of full activity or require minimal assistance; characterised by relatively severe disability; able to walk 
some 300 m without aid or rest 
Ambulatory without aid or rest for about 200 m; disability severe enough to impair full daily activities 
(can work a full day without special provisions) 
Ambulatory without aid or rest for about 100m; disability severe enough to preclude full daily activities 
Intermittent or unilateral constant assistance (cane, crutch, brace) required to walk about 100m with or 
without resting 
Constant bilateral assistance (canes, crutches, braces) required to walk about 20m without resting 
Unable to walk beyond approximately 5 m even with aid, essentially restricted to wheelchair; wheels self in 
standard wheelchair and transfers alone; up and about in wheelchair some 12 hours a day 
Unable to take more than a few steps; restricted to wheelchair; may need aid in transfer; wheels self but cannot 
carry on in standard wheelchair a full day; may require motorised wheelchair 
Essentially restricted to bed or chair or perambulated in wheelchair, but may be out of bed itself much of the day; 
retains many self-care functions; generally has effective use of arms 
Essentially restricted to bed much of day; has some effective use of arms, retains some self care functions 
Confined to bed; can still communicate and eat 
Totally helpless bed patient; unable to communicate effectively or eat/swallow 
Death due to MS 
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